Shares of Eli Lilly LLY rose more than 7% on Friday after the company announced several positive developments related to its ...

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society of Hematology Annual Meeting and published in The ...

The Jaypirca application moves to the EC for a decision, expected within the next one to two months.

In today's ACT Brief, we recap key themes from DIA 2026 on operational priorities and regulatory shifts, examine ...

Eli Lilly and Co (NYSE:LLY) shares climbed nearly 6% on Friday after the European Medicines Agency's Committee for Medicinal ...

September is Leukemia and Lymphoma Awareness Month. An estimated 1,629,474 people in the United States (US) are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes ...

With a median follow-up of 64 months, 176 (78%) S#2 patients required first-line therapy as follows: 113 with CIT, 45 with BTKi, 12 with BCL2i and 6 with unspecified other treatment. Among the nS#2 ...

Diagnostic challenges in leukemia—a fatal malignancy affecting blood cells—are immense due to its diverse manifestations and subtypes. Acute lymphoblastic leukemia is one of the most common types of ...